9 July 2020 - - US-based contract research organization Biorasi has started its third COVID-19 clinical trial for 2020, the company said.

Taking place across the United States and Europe, the goal of the study is to evaluate the efficacy and safety of the candidate drug as an antiviral agent in hospitalized patients diagnosed with COVID-19 infections.

The upcoming study will focus on the effect and virulence of SARS-CoV-2 and explore the prevention of potential superinfections in the lungs.

Approximately 100 patients will be recruited to take part, with results in hand by 2Q21.

This is Biorasi's third COVID-19 trial for 2020. The first focused on the treatment of lung injuries caused by COVID-19. 

The second study targeted the efficacy of a prophylactic medication for maintaining the health and safety of healthcare personnel treating patients with the coronavirus.

Biorasi is in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.

Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC.